AR071618A1 - Octahidroquinazolonas y benzo[b]{1,4]oxazinas heterociclicas, agonistas de receptores muscarinicos, composiciones farmaceuticas que las contienen, metodo de preparacion y uso de las mismas en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia. - Google Patents
Octahidroquinazolonas y benzo[b]{1,4]oxazinas heterociclicas, agonistas de receptores muscarinicos, composiciones farmaceuticas que las contienen, metodo de preparacion y uso de las mismas en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia.Info
- Publication number
- AR071618A1 AR071618A1 ARP090101597A ARP090101597A AR071618A1 AR 071618 A1 AR071618 A1 AR 071618A1 AR P090101597 A ARP090101597 A AR P090101597A AR P090101597 A ARP090101597 A AR P090101597A AR 071618 A1 AR071618 A1 AR 071618A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- cycloalkyl
- halogenated
- heterocycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula 1, una sal farmacéuticamente aceptable del mismo, diastereomero, enantiomero, o mezcla de los mismos, en donde cada R1 se selecciona independientemente de fluoro, cicloalquilo C3-7, alquilo C1-7, alquenilo C2-6, alquinilo C2-6, alcoxi C1-7, cicloalcoxi C3-7-alquilo C1-6, alcoxi C1-6-alquilo C1-6, alqueniloxi C2-6, alqueniloxi C2-6-alquilo C1-6, alquiniloxi C2-6, alquiniloxi C2-6-alquilo C1-6, alquilamino C1-6, di-alquilamino C1-6, heterocicloalquiloxi C3-7, heterocicloalquilo C3-7, aril C6-10-alcoxi C1-3, aril C6-10-alquilo C1-3, heteroaril C3-9-alcoxi C1-3, heteroaril C3-9-alquilo C1-3, heterocicloalquil C3-7-alcoxi C1-3 , heterocicloalquil C3-7-alquilo C1-3, cicloalquiloxi C3-7, cicloalquil C3-7-alquilo C1-3, cicloalquil C3-7-alcoxi C1-3 y cicloalquil C3-7-alcoxi C1-3-alquilo C1-3, en donde dichos cicloalquilo C3-7, alquilo C1-7, alquenilo C2-6, alquinilo C2-6, alcoxi C1-7, cicloalcoxi C3-7-alquilo C1-6, alcoxi C1-6-alquilo C1-6, alqueniloxi C2-6, alqueniloxi C2-6-alquilo C1-6, alquiniloxi C2-6, alquiniloxi C2-6-alquilo C1-6, alquilamino C1-6, di-alquilamino C1-6, heterocicloalquiloxi C3-7, heterocicloalquilo C3-7, aril C6-10-alcoxi C1-3, aril C6-10-alquilo C1-3, heteroaril C3-9-alcoxi C1-3, heteroaril C3-9-alquilo C1-3, heterocicloalquil C3-7-alcoxi C1-3, heterocicloalquil C3-7-alquilo C1-3, cicloalquiloxi C3-7, cicloalquil C3-7-alquilo C1-3, cicloalquil C3-7-alcoxi C1-3 y cicloalquil C3-7-alcoxi C1-3-alquilo C1-3 están sustituidos opcionalmente con uno o más grupos seleccionados de fenilo, cicloalquilo C3-6, heterocicloalquilo C2-5, heteroarilo C3-5, -CN, -SR, -OR, -O(CH2)p-OR, R, -C(=O)-R, -CO2R, -SO2R, - SO2NRR', halogeno, -NO2, -NRR', -(CH2)pNRR', y -C(=O)-NRR'; cada R2 se selecciona independientemente de halogeno, alquilo C1-6, cicloalquilo C3-7, alquilo C1-6 halogenado, alcoxi C1-6, y alcoxi C1-6 halogenado; cada R3 se selecciona independientemente de halogeno, alquilo C1-6, cicloalquilo C3-7, alquilo C1-6 halogenado, CN, alcoxi C1-6, y alcoxi C1-6 halogenado; o dos R3 juntos forman un alquileno C1-6, alquilenoxi C1-6, o alquileno C1-6 halogenado; R4 es H, alquilo C1-6 o haloalquilo C1-6; q es 1, 2, 3 o 4; p es 2, 3, o 4; s es 0, 1, 2, 3, o 4; t es 0, 1, 2, 3 o 4; n es 0, 1, 2, 3 o 4; m es 0, 1, 2, 3 o 4; Y es -CR5R6-, -O-, o -S-; X es -CR5R6-, -NR7-, -O-, o -S-; cada R5, R6 y R7 se seleccionan independientemente de H, alquilo C1-6, alquenilo C2-6, y alquilo C1-6 halogenado; y cada R y R' son independientemente alquilo C1-6, alquenilo C2-6, o alquilo C1-6 halogenado, con la salvedad de que al menos uno de X e Y es -CR5R6-, y con la salvedad adicional en el sentido de que el compuesto no es (4aS,8aS)-4-(1-(4-(etoximetil)-1-metilciclohexil)piperidin-4-il)hexahidro-2H-benzo[b][1,4]oxazin-3(4H)-ona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5034308P | 2008-05-05 | 2008-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071618A1 true AR071618A1 (es) | 2010-06-30 |
Family
ID=41257503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101597A AR071618A1 (es) | 2008-05-05 | 2009-05-04 | Octahidroquinazolonas y benzo[b]{1,4]oxazinas heterociclicas, agonistas de receptores muscarinicos, composiciones farmaceuticas que las contienen, metodo de preparacion y uso de las mismas en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20090275574A1 (es) |
| EP (1) | EP2285798A4 (es) |
| JP (1) | JP2011519922A (es) |
| KR (1) | KR20110011654A (es) |
| CN (1) | CN102083812A (es) |
| AR (1) | AR071618A1 (es) |
| AU (1) | AU2009244944A1 (es) |
| BR (1) | BRPI0912537A2 (es) |
| CA (1) | CA2723679A1 (es) |
| MX (1) | MX2010011841A (es) |
| PE (1) | PE20091831A1 (es) |
| RU (1) | RU2010143984A (es) |
| TW (1) | TW200951119A (es) |
| UY (1) | UY31805A (es) |
| WO (1) | WO2009136850A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200815405A (en) * | 2006-06-09 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| AU2011346749A1 (en) * | 2010-12-22 | 2013-05-02 | Purdue Pharma L.P. | Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof |
| WO2015138237A1 (en) | 2014-03-10 | 2015-09-17 | Mary Kay Inc. | Skin lightening compositions |
| AU2020242662A1 (en) | 2019-03-15 | 2021-10-07 | Bayer Aktiengesellschaft | Specifically substituted 3-phenyl-5-spirocyclopentyl-3-pyrrolin-2-ones and their use as herbicides |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU701127B2 (en) * | 1994-10-27 | 1999-01-21 | Merck & Co., Inc. | Muscarine antagonists |
| JP4484368B2 (ja) * | 1998-10-16 | 2010-06-16 | 大日本住友製薬株式会社 | キナゾリノン誘導体 |
| SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| ES2193875B2 (es) * | 2002-04-09 | 2005-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
| AR045939A1 (es) * | 2003-09-25 | 2005-11-16 | Solvay Pharm Bv | Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos |
| JP2006188466A (ja) * | 2005-01-07 | 2006-07-20 | Dainippon Sumitomo Pharma Co Ltd | 過活動膀胱治療薬としてのキナゾリノン誘導体 |
| GB0605784D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| US8119661B2 (en) * | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
-
2009
- 2009-04-30 US US12/432,818 patent/US20090275574A1/en not_active Abandoned
- 2009-05-04 RU RU2010143984/04A patent/RU2010143984A/ru not_active Application Discontinuation
- 2009-05-04 KR KR1020107027223A patent/KR20110011654A/ko not_active Application Discontinuation
- 2009-05-04 UY UY0001031805A patent/UY31805A/es unknown
- 2009-05-04 BR BRPI0912537A patent/BRPI0912537A2/pt not_active IP Right Cessation
- 2009-05-04 CN CN2009801261650A patent/CN102083812A/zh active Pending
- 2009-05-04 CA CA2723679A patent/CA2723679A1/en not_active Abandoned
- 2009-05-04 WO PCT/SE2009/050477 patent/WO2009136850A1/en active Application Filing
- 2009-05-04 JP JP2011508444A patent/JP2011519922A/ja active Pending
- 2009-05-04 MX MX2010011841A patent/MX2010011841A/es not_active Application Discontinuation
- 2009-05-04 AR ARP090101597A patent/AR071618A1/es unknown
- 2009-05-04 TW TW098114745A patent/TW200951119A/zh unknown
- 2009-05-04 AU AU2009244944A patent/AU2009244944A1/en not_active Abandoned
- 2009-05-04 EP EP09742932A patent/EP2285798A4/en not_active Withdrawn
- 2009-05-05 PE PE2009000610A patent/PE20091831A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY31805A (es) | 2010-01-05 |
| RU2010143984A (ru) | 2012-06-20 |
| CN102083812A (zh) | 2011-06-01 |
| JP2011519922A (ja) | 2011-07-14 |
| PE20091831A1 (es) | 2009-12-31 |
| EP2285798A4 (en) | 2013-01-02 |
| WO2009136850A1 (en) | 2009-11-12 |
| US20090275574A1 (en) | 2009-11-05 |
| MX2010011841A (es) | 2010-11-26 |
| BRPI0912537A2 (pt) | 2015-10-13 |
| EP2285798A1 (en) | 2011-02-23 |
| TW200951119A (en) | 2009-12-16 |
| CA2723679A1 (en) | 2009-11-12 |
| AU2009244944A1 (en) | 2009-11-12 |
| KR20110011654A (ko) | 2011-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071245A1 (es) | Derivados de piperidina como antagonistas de receptores muscarinicos, procesos de obtencion y composiciones farmaceuticas | |
| AR071618A1 (es) | Octahidroquinazolonas y benzo[b]{1,4]oxazinas heterociclicas, agonistas de receptores muscarinicos, composiciones farmaceuticas que las contienen, metodo de preparacion y uso de las mismas en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia. | |
| AR061306A1 (es) | Compuestos de pirrolidin-3-1l-piperidina como agonistas de receptores muscarinicos | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| JP2016538313A5 (es) | ||
| AR061305A1 (es) | Agonistas de receptores muscarinicos | |
| PE20090160A1 (es) | COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA | |
| AR070534A1 (es) | Agonistas de receptores muscarinicos | |
| AR050617A1 (es) | Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas | |
| AR060729A1 (es) | Compuestos agonistas de los receptores muscarinicos | |
| AR047424A1 (es) | Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos | |
| RU2006132463A (ru) | Антагонисты рецептора хемокина | |
| PE20060150A1 (es) | Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion | |
| AR074814A1 (es) | Pirimidinas sustituidas como antagonistas del receptor ccr2 y usos de las mismas en medicamentos. | |
| AR051638A1 (es) | Compuestos de piperidinilo y su uso para tratar desordenes de respuesta al bloqueo de los canales de calcio tipo n | |
| AR071644A1 (es) | Plaguicidas mesoionicos | |
| AR051461A1 (es) | Compuesto de pirazolo[1,5-a]pirimidin-7-il-amina forma poliformica 1 de [3-(4-metoxi-2-metil-fenil)-2,5-dimetil-pirazolo[1,5-a]pirimidin-7-il]-[(s)-1-(3-metil-[1,2,4]oxadiazol-5-il)-propil]-amina, composicion farmaceutica que lo comprende y su uso para prepararla | |
| SV1999000119A (es) | Benzazoles consistentes en derivados de benzoxazol, benzthiazol y benzimidazol | |
| AR062154A1 (es) | Derivados de pirazoles como inhibidores p450 (cyp450) | |
| PE20061156A1 (es) | Derivados de benzamida como agentes inhibidores del transportador de glicina | |
| PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
| PE20090621A1 (es) | Pirrolidina-aril-eteres como antagonistas de receptores de nk3 | |
| PE20090898A1 (es) | Pirrolidina-aril-eteres como antagonistas de receptor de nk3 | |
| RU2014123109A (ru) | Антибиотические производные 2-оксо-оксазолидин-3, 5-диила | |
| AR034249A1 (es) | Uso de derivados de quinolina como antagonistas alfa-2; compuestos derivados de quinolina y sus composiciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |